Compare EPM & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EPM | LCTX |
|---|---|---|
| Founded | 2003 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.3M | 407.7M |
| IPO Year | 1996 | N/A |
| Metric | EPM | LCTX |
|---|---|---|
| Price | $3.64 | $1.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $4.93 | $4.25 |
| AVG Volume (30 Days) | 458.7K | ★ 1.3M |
| Earning Date | 02-10-2026 | 11-06-2025 |
| Dividend Yield | ★ 13.15% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $85,232,000.00 | $10,816,000.00 |
| Revenue This Year | N/A | $6.32 |
| Revenue Next Year | $1.22 | $124.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.05 |
| 52 Week Low | $3.51 | $0.37 |
| 52 Week High | $5.70 | $2.09 |
| Indicator | EPM | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.28 | 46.51 |
| Support Level | $4.02 | $1.63 |
| Resistance Level | $3.62 | $1.77 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 18.54 | 28.21 |
Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.